Human cytomegalovirus 65 kDa Phosphoprotein Market Report

Global and Region Human cytomegalovirus 65 kDa Phosphoprotein Market Demand & Opportunity Outlook 2022-2028

  • POSTDATE：Aug 02, 2022
  • PAGES：148
  • REPORT CODE：GMM991038
  • REPORT SUMMARY
  • TABLE OF CONTENTS

  • The report details the trend, potential and market size of Human cytomegalovirus 65 kDa Phosphoprotein market, and analyzes the current situation and prospects of the market from both qualitative and quantitative aspects, which can be roughly divided into three parts.

    The first part (Chapter1-7) mainly covers the qualitative analysis of Human cytomegalovirus 65 kDa Phosphoproteinmarket, defines the market attractiveness level of Human cytomegalovirus 65 kDa Phosphoprotein market through Porter's Five Forces Analysis, and summarizes the different factors in the overall environment through PEST analysis. Understand the distribution of industrial chain value in each link of industrial chain through the analysis of industrial chain structure. Thus estimate the market space of each link.

    The second part (Chapter8-12), based on the segmentation of Human cytomegalovirus 65 kDa Phosphoprotein industry, describes the types of Human cytomegalovirus 65 kDa Phosphoprotein market, the applications of major players and the market size, and deeply analyzes the current situation of the global Human cytomegalovirus 65 kDa Phosphoprotein market and the development prospects and opportunities of Human cytomegalovirus 65 kDa Phosphoprotein industry.

    The third part (Chapter14-15) includes the market positions of the major players and information on the market participants, which will help you gain a comprehensive understanding of the current competitive situation and potential growth opportunities in the market.

    As COVID-19 continues to impact the global economy in 2022, the report also considers the short - and long-term impacts of COVID-19 on the global Human cytomegalovirus 65 kDa Phosphoprotein market in Chapter 13.

    By Player:

    • Vical Inc

    • Immunomic Therapeutics Inc

    • Vaximm AG

    • VBI Vaccines Inc

    • Astellas Pharma Inc

    • Hookipa Biotech AG

    • Vakzine Projekt Management GmbH

    By Type:

    • HB-101

    • CyMVectin

    • ASP-0113

    • PepVax

    • Others

    By End-User:

    • Brain Tumor

    • Hemotaological Tumor

    • Kidney Transplant Rejection

    • Liver Transplant Rejection

    • Others

    By Geography:

    • United States

    • Europe

    • China

    • Japan

    • India

    • South Korea

  • TABLE OF CONTENT

    1 Introduction

    • 1.1 Market Definition

    • 1.2 Market Segment Analysis

    • 1.3 Market Size 2022

    • 1.4 Human cytomegalovirus 65 kDa Phosphoprotein Market Outlook: Forecast for 2022 - 2028

    • 1.5 Pricing Analysis

    2 Executive Summary

    3 Human cytomegalovirus 65 kDa Phosphoprotein Market Lineage Outlook

    • 3.1 Parent Market Outlook

    • 3.2 Related/Ancillary Market Outlook

    • 3.3 Penetration & Growth Prospect Mapping, 2022

    4 Market Analysis Tools: Porter's Five Forces

    • 4.1 Supplier Power

    • 4.2 Buyer Power

    • 4.3 Substitution Threat

    • 4.4 Threat of New Entrants

    • 4.5 Competitive Rivalry

    5 Human cytomegalovirus 65 kDa Phosphoprotein Industry Analysis - PEST (Political & Legal, Economic, Social, and Technological)

    • 5.1 Political/Legal Landscape

    • 5.2 Economic Landscape

    • 5.3 Social Landscape

    • 5.4 Technology Landscape

    6 Human cytomegalovirus 65 kDa Phosphoprotein Market - Value Chain Analysis

    • 6.1 Industry's Value Chain Analysis

    • 6.2 Product Life Cycle

    • 6.3 User Perspective Analysis

    7 Region and Country-wise Human cytomegalovirus 65 kDa Phosphoprotein Market Analysis and Outlook to 2022

    • 7.1 Global Human cytomegalovirus 65 kDa Phosphoprotein Consumption (2017-2022)

    • 7.2 United States Human cytomegalovirus 65 kDa Phosphoprotein Consumption (2017-2022)

    • 7.3 Europe Human cytomegalovirus 65 kDa Phosphoprotein Consumption (2017-2022)

    • 7.4 China Human cytomegalovirus 65 kDa Phosphoprotein Consumption (2017-2022)

    • 7.5 Japan Human cytomegalovirus 65 kDa Phosphoprotein Consumption (2017-2022)

    • 7.6 India Human cytomegalovirus 65 kDa Phosphoprotein Consumption (2017-2022)

    • 7.7 South Korea Human cytomegalovirus 65 kDa Phosphoprotein Consumption (2017-2022)

    8 Region and Country-wise Human cytomegalovirus 65 kDa Phosphoprotein Market Analysis and Outlook to 2028

    • 8.1 Global Human cytomegalovirus 65 kDa Phosphoprotein Consumption Forecast (2022-2028)

    • 8.2 United States Human cytomegalovirus 65 kDa Phosphoprotein Consumption Forecast (2022-2028)

    • 8.3 Europe Human cytomegalovirus 65 kDa Phosphoprotein Consumption Forecast (2022-2028)

    • 8.4 China Human cytomegalovirus 65 kDa Phosphoprotein Consumption Forecast (2022-2028)

    • 8.5 Japan Human cytomegalovirus 65 kDa Phosphoprotein Consumption Forecast (2022-2028)

    • 8.6 India Human cytomegalovirus 65 kDa Phosphoprotein Consumption Forecast (2022-2028)

    • 8.7 South Korea Human cytomegalovirus 65 kDa Phosphoprotein Consumption Forecast (2022-2028)

    9 Global Human cytomegalovirus 65 kDa Phosphoprotein Market Outlook by Types and Applications to 2022

    • 9.1 Global Human cytomegalovirus 65 kDa Phosphoprotein Consumption and Growth Rate by Type (2017-2022)

      • 9.1.1 Global HB-101 Consumption and Growth Rate (2017-2022)

      • 9.1.2 Global CyMVectin Consumption and Growth Rate (2017-2022)

      • 9.1.3 Global ASP-0113 Consumption and Growth Rate (2017-2022)

      • 9.1.4 Global PepVax Consumption and Growth Rate (2017-2022)

      • 9.1.5 Global Others Consumption and Growth Rate (2017-2022)

    • 9.2 Global Human cytomegalovirus 65 kDa Phosphoprotein Consumption and Growth Rate by Application (2017-2022)

      • 9.2.1 Global Brain Tumor Consumption and Growth Rate (2017-2022)

      • 9.2.2 Global Hemotaological Tumor Consumption and Growth Rate (2017-2022)

      • 9.2.3 Global Kidney Transplant Rejection Consumption and Growth Rate (2017-2022)

      • 9.2.4 Global Liver Transplant Rejection Consumption and Growth Rate (2017-2022)

      • 9.2.5 Global Others Consumption and Growth Rate (2017-2022)

    10 Global Human cytomegalovirus 65 kDa Phosphoprotein Market Outlook by Types and Applications to 2028

    • 10.1 Global Human cytomegalovirus 65 kDa Phosphoprotein Consumption Forecast and Growth Rate by Type (2022-2028)

      • 10.1.1 Global HB-101 Consumption Forecast and Growth Rate (2022-2028)

      • 10.1.2 Global CyMVectin Consumption Forecast and Growth Rate (2022-2028)

      • 10.1.3 Global ASP-0113 Consumption Forecast and Growth Rate (2022-2028)

      • 10.1.4 Global PepVax Consumption Forecast and Growth Rate (2022-2028)

      • 10.1.5 Global Others Consumption Forecast and Growth Rate (2022-2028)

    • 10.2 Global Human cytomegalovirus 65 kDa Phosphoprotein Consumption Forecast and Growth Rate by Application (2022-2028)

      • 10.2.1 Global Brain Tumor Consumption Forecast and Growth Rate (2022-2028)

      • 10.2.2 Global Hemotaological Tumor Consumption Forecast and Growth Rate (2022-2028)

      • 10.2.3 Global Kidney Transplant Rejection Consumption Forecast and Growth Rate (2022-2028)

      • 10.2.4 Global Liver Transplant Rejection Consumption Forecast and Growth Rate (2022-2028)

      • 10.2.5 Global Others Consumption Forecast and Growth Rate (2022-2028)

    11 Global Human cytomegalovirus 65 kDa Phosphoprotein Import and Export Analysis (Top 5 Countries)

    • 11.1 Global Human cytomegalovirus 65 kDa Phosphoprotein Import by Region (Top 5 Countries) (2017-2028)

    • 11.2 Global Human cytomegalovirus 65 kDa Phosphoprotein Export by Region (Top 5 Countries) (2017-2028)

    12 Coronavirus Disease (COVID-19) Impact

    • 12.1 Industry Impact Analysis

    • 12.2 Human cytomegalovirus 65 kDa Phosphoprotein Market Outlook to 2028 - COVID-19 Affected Forecasts

    13 Competition Matrix

    • 13.1 Target Markets

    • 13.2 Comprehensive Analysis of Products in Competitive Markets

    14 Global Human cytomegalovirus 65 kDa Phosphoprotein Market Competitive Analysis

    • 14.1 Vical Inc

      • 14.1.1 Vical Inc Company Details

      • 14.1.2 Vical Inc Human cytomegalovirus 65 kDa Phosphoprotein Sales, Price, Value and Gross Profit (2017-2022)

      • 14.1.3 Vical Inc Human cytomegalovirus 65 kDa Phosphoprotein Product and Service

    • 14.2 Immunomic Therapeutics Inc

      • 14.2.1 Immunomic Therapeutics Inc Company Details

      • 14.2.2 Immunomic Therapeutics Inc Human cytomegalovirus 65 kDa Phosphoprotein Sales, Price, Value and Gross Profit (2017-2022)

      • 14.2.3 Immunomic Therapeutics Inc Human cytomegalovirus 65 kDa Phosphoprotein Product and Service

    • 14.3 Vaximm AG

      • 14.3.1 Vaximm AG Company Details

      • 14.3.2 Vaximm AG Human cytomegalovirus 65 kDa Phosphoprotein Sales, Price, Value and Gross Profit (2017-2022)

      • 14.3.3 Vaximm AG Human cytomegalovirus 65 kDa Phosphoprotein Product and Service

    • 14.4 VBI Vaccines Inc

      • 14.4.1 VBI Vaccines Inc Company Details

      • 14.4.2 VBI Vaccines Inc Human cytomegalovirus 65 kDa Phosphoprotein Sales, Price, Value and Gross Profit (2017-2022)

      • 14.4.3 VBI Vaccines Inc Human cytomegalovirus 65 kDa Phosphoprotein Product and Service

    • 14.5 Astellas Pharma Inc

      • 14.5.1 Astellas Pharma Inc Company Details

      • 14.5.2 Astellas Pharma Inc Human cytomegalovirus 65 kDa Phosphoprotein Sales, Price, Value and Gross Profit (2017-2022)

      • 14.5.3 Astellas Pharma Inc Human cytomegalovirus 65 kDa Phosphoprotein Product and Service

    • 14.6 Hookipa Biotech AG

      • 14.6.1 Hookipa Biotech AG Company Details

      • 14.6.2 Hookipa Biotech AG Human cytomegalovirus 65 kDa Phosphoprotein Sales, Price, Value and Gross Profit (2017-2022)

      • 14.6.3 Hookipa Biotech AG Human cytomegalovirus 65 kDa Phosphoprotein Product and Service

    • 14.7 Vakzine Projekt Management GmbH

      • 14.7.1 Vakzine Projekt Management GmbH Company Details

      • 14.7.2 Vakzine Projekt Management GmbH Human cytomegalovirus 65 kDa Phosphoprotein Sales, Price, Value and Gross Profit (2017-2022)

      • 14.7.3 Vakzine Projekt Management GmbH Human cytomegalovirus 65 kDa Phosphoprotein Product and Service

    15 Appendix


    TABLE OF CHARTS

    • Table Definition of Human cytomegalovirus 65 kDa Phosphoprotein

    • Figure Human cytomegalovirus 65 kDa Phosphoprotein Picture

    • Table Global Human cytomegalovirus 65 kDa Phosphoprotein Market Size and Forecast 2022 - 2028 (USD million)

    • Figure Global Human cytomegalovirus 65 kDa Phosphoprotein Market Size and Forecast 2022 - 2028 (USD million)

    • Figure Global Human cytomegalovirus 65 kDa Phosphoprotein Market: Year-over-year Growth 2022 - 2028 (%)

    • Table Parent Market Analysis

    • Figure Parent Market Price

    • Table Related/Ancillary Market Outlook Analysis

    • Table Supplier Power Analysis

    • Table Buyer Power Analysis

    • Table Substitution Threat Analysis

    • Table Threat of New Entrants Analysis

    • Table Competitive Rivalry Analysis

    • Figure Global Human cytomegalovirus 65 kDa Phosphoprotein Consumption by Country (2017-2022)

    • Figure United States Human cytomegalovirus 65 kDa Phosphoprotein Consumption and Growth Rate (2017-2022)

    • Table Europe Human cytomegalovirus 65 kDa Phosphoprotein Consumption and Growth Rate (2017-2022)

    • Figure China Human cytomegalovirus 65 kDa Phosphoprotein Consumption and Growth Rate (2017-2022)

    • Figure Japan Human cytomegalovirus 65 kDa Phosphoprotein Consumption and Growth Rate (2017-2022)

    • Figure India Human cytomegalovirus 65 kDa Phosphoprotein Consumption and Growth Rate (2017-2022)

    • Figure South Korea Human cytomegalovirus 65 kDa Phosphoprotein Consumption and Growth Rate (2017-2022)

    • Figure Global Human cytomegalovirus 65 kDa Phosphoprotein Consumption Forecast by Country (2022-2028)

    • Figure United States Human cytomegalovirus 65 kDa Phosphoprotein Consumption Forecast and Growth Rate (2022-2028)

    • Table Europe Human cytomegalovirus 65 kDa Phosphoprotein Consumption Forecast and Growth Rate (2022-2028)

    • Figure China Human cytomegalovirus 65 kDa Phosphoprotein Consumption Forecast and Growth Rate (2022-2028)

    • Figure Japan Human cytomegalovirus 65 kDa Phosphoprotein Consumption Forecast and Growth Rate (2022-2028)

    • Figure India Human cytomegalovirus 65 kDa Phosphoprotein Consumption Forecast and Growth Rate (2022-2028)

    • Figure South Korea Human cytomegalovirus 65 kDa Phosphoprotein Consumption Forecast and Growth Rate (2022-2028)

    • Figure Global HB-101 Consumption and Growth Rate (2017-2022)

    • Figure Global CyMVectin Consumption and Growth Rate (2017-2022)

    • Figure Global ASP-0113 Consumption and Growth Rate (2017-2022)

    • Figure Global PepVax Consumption and Growth Rate (2017-2022)

    • Figure Global Others Consumption and Growth Rate (2017-2022)

    • Figure Global Brain Tumor Consumption and Growth Rate (2017-2022)

    • Figure Global Hemotaological Tumor Consumption and Growth Rate (2017-2022)

    • Figure Global Kidney Transplant Rejection Consumption and Growth Rate (2017-2022)

    • Figure Global Liver Transplant Rejection Consumption and Growth Rate (2017-2022)

    • Figure Global Others Consumption and Growth Rate (2017-2022)

    • Figure Global HB-101 Consumption Forecast and Growth Rate (2022-2028)

    • Figure Global CyMVectin Consumption Forecast and Growth Rate (2022-2028)

    • Figure Global ASP-0113 Consumption Forecast and Growth Rate (2022-2028)

    • Figure Global PepVax Consumption Forecast and Growth Rate (2022-2028)

    • Figure Global Others Consumption Forecast and Growth Rate (2022-2028)

    • Figure Global Brain Tumor Consumption Forecast and Growth Rate (2022-2028)

    • Figure Global Hemotaological Tumor Consumption Forecast and Growth Rate (2022-2028)

    • Figure Global Kidney Transplant Rejection Consumption Forecast and Growth Rate (2022-2028)

    • Figure Global Liver Transplant Rejection Consumption Forecast and Growth Rate (2022-2028)

    • Figure Global Others Consumption Forecast and Growth Rate (2022-2028)

    • Table Global Human cytomegalovirus 65 kDa Phosphoprotein Import by Region (Top 5 Countries) (2017-2028)

    • Table Global Human cytomegalovirus 65 kDa Phosphoprotein Export by Region (Top 5 Countries) (2017-2028)

    • Table Vical Inc (Foundation Year, Company Profile and etc.)

    • Table Vical Inc Human cytomegalovirus 65 kDa Phosphoprotein Sales, Price, Value and Gross Profit (2017-2022)

    • Table Vical Inc Human cytomegalovirus 65 kDa Phosphoprotein Product and Service

    • Table Immunomic Therapeutics Inc (Foundation Year, Company Profile and etc.)

    • Table Immunomic Therapeutics Inc Human cytomegalovirus 65 kDa Phosphoprotein Sales, Price, Value and Gross Profit (2017-2022)

    • Table Immunomic Therapeutics Inc Human cytomegalovirus 65 kDa Phosphoprotein Product and Service

    • Table Vaximm AG (Foundation Year, Company Profile and etc.)

    • Table Vaximm AG Human cytomegalovirus 65 kDa Phosphoprotein Sales, Price, Value and Gross Profit (2017-2022)

    • Table Vaximm AG Human cytomegalovirus 65 kDa Phosphoprotein Product and Service

    • Table VBI Vaccines Inc (Foundation Year, Company Profile and etc.)

    • Table VBI Vaccines Inc Human cytomegalovirus 65 kDa Phosphoprotein Sales, Price, Value and Gross Profit (2017-2022)

    • Table VBI Vaccines Inc Human cytomegalovirus 65 kDa Phosphoprotein Product and Service

    • Table Astellas Pharma Inc (Foundation Year, Company Profile and etc.)

    • Table Astellas Pharma Inc Human cytomegalovirus 65 kDa Phosphoprotein Sales, Price, Value and Gross Profit (2017-2022)

    • Table Astellas Pharma Inc Human cytomegalovirus 65 kDa Phosphoprotein Product and Service

    • Table Hookipa Biotech AG (Foundation Year, Company Profile and etc.)

    • Table Hookipa Biotech AG Human cytomegalovirus 65 kDa Phosphoprotein Sales, Price, Value and Gross Profit (2017-2022)

    • Table Hookipa Biotech AG Human cytomegalovirus 65 kDa Phosphoprotein Product and Service

    • Table Vakzine Projekt Management GmbH (Foundation Year, Company Profile and etc.)

    • Table Vakzine Projekt Management GmbH Human cytomegalovirus 65 kDa Phosphoprotein Sales, Price, Value and Gross Profit (2017-2022)

    • Table Vakzine Projekt Management GmbH Human cytomegalovirus 65 kDa Phosphoprotein Product and Service


Report Version Choose

Report

BUY NOW

Our Customers

Beyond grateful for the confidence and support from all partners and customers.A win-win situation is our ultimate pursuit.

Beyond Consulting, Future is Feasible

We provide more professional and intelligent market reports to complement your business decisions.

CONTACT US